

The *SLC40A1* R178Q mutation is a recurrent cause of hemochromatosis and is associated with a novel pathogenic mechanism

Chandran Ka,^{1,2,3*} Julie Guellec,^{1,3,4*} Xavier Pepermans,⁵ Caroline Kannengiesser,^{3,6,7} Cécile Ged,^{7,8} Wim Wuyts,⁹ David Cassiman,¹⁰ Victor de Ledinghen,¹¹ Bruno Varet,¹² Caroline de Kerguenec,¹³ Claire Oudin,⁶ Isabelle Gourlaouen,^{1,3} Thibaud Lefebvre,⁶ Claude Férec,^{1,2,7} Isabelle Callebaut¹⁴ and Gérald Le Gac^{1,2,3,7}

¹UMR1078, INSERM, Université Bretagne Loire – Université de Bretagne Occidentale, Etablissement Français du Sang – Bretagne, Institut Brestois Santé-Agro-Matière, Brest, France; ²Laboratoire de Génétique Moléculaire et Histocompatibilité, CHRU de Brest, Hôpital Morvan, France; ³Laboratory of Excellence GR-Ex, Paris, France; ⁴Association Gaetan Saleun, Brest, France; ⁵Center for Human Genetics, University Hospital of St-Luc, Brussels, Belgium; ⁶UMR1149, INSERM, Centre de Recherche sur l'Inflammation, Université Paris Diderot, AP-HP, Hôpital Bichat, Département de Génétique, France; ⁷On behalf of the French National Network for the Molecular Diagnosis of Inherited Iron Overload Disorders (J. Rochette, E. Cadet, C. Kannengiesser, H. Puy, C. Ged, H. de Verneuil, G. Le Gac, C. Férec, S. Pissard, V. Gérolami), Brest, France; ⁸INSERM U1035, BMGIC, CHU de Bordeaux, Laboratoire de Biochimie et Biologie Moléculaire, France; ⁹Department of Medical Genetics, University and University Hospital of Antwerp, Edegem, Belgium; ¹⁰Department of Gastroenterology-Hepatology and Metabolic Center, University Hospital of Leuven, Belgium; ¹¹Department of Gastroenterology and Digestive Oncology, University Hospital of Bordeaux, France; ¹²Université Paris Descartes et AP-HP, Hôpital Necker, Service d'Hématologie, France; ¹³AP-HP, Hôpital Beaujon, Département d'Hépatologie, Clichy, France and ¹⁴UMR7590, CNRS, Sorbonne Universités, Université Pierre et Marie Curie-Paris, France

**CK and JG contributed equally to this work*

©2018 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2018.189845

Received: January 29, 2018.

Accepted: July 6, 2018.

Pre-published: July 12, 2018.

Correspondence: gerald.legac@univ-brest.fr

Methods

Plasmid constructs

The wild-type FPN1-V5 plasmid construct was generated by cloning full-length human *SLC40A1* cDNA (Genbank accession number NM_0414585.5) into the pcDNA3.1-V5-His-TOPO vector (ThermoFisher Scientific). The same strategy was adopted to generate the HLA(A)-V5 plasmid construct. All ferroportin mutations were introduced in the pcDNA3.1-FPN/V5 vector by using the QuickChange Site-Directed mutagenesis kit, according to the manufacturer's instructions (Agilent Technologies). Sequencing analyses were performed to check the integrity of all the plasmid constructs (full length *SLC40A1* cDNA sequenced after each site-directed mutagenesis).

CULTURE AND TRANSFECTION OF HUMAN EPITHELIAL KIDNEY (HEK)293T CELLS

HEK293T cells, from the American Type Culture Collection, were incubated at 37°C in a 5% CO₂ humidified atmosphere and propagated in Dulbecco's modified Eagle's medium (DMEM; Lonza, Walkersville, MD, USA) supplemented with 10% fetal bovine serum and 5 µg/mL plasmocin (InvivoGen). Cells were transiently transfected using JetPEI (Polyplus), according to the manufacturer's instructions, and a 2:1 transfection reagent (µL)/plasmid DNA ratio (µg).

ISOLATION OF CELL SURFACE PROTEINS AND WESTERN BLOT ANALYSIS

Membrane proteins were biotinylated and purified using the Pierce Cell Surface Protein Isolation Kit, according to the manufacturer's instructions (ThermoFisher Scientific). Western blot analysis was performed using mouse horseradish peroxidase-conjugated monoclonal antibody against V5 (ThermoFisher Scientific). The membranes were incubated with the Luminata Forte substrate, according to the manufacturer's instructions (Merck-Millipore), and digitized for pattern analysis using the GeneGnome system (Syngene).

DENSITOMETRY STUDY

To quantitate ferroportin expression levels on the cell surface, the optic density of *SLC40A1/V5* and *HLA-A/V5* protein bands was measured on digital images by the GeneTools software (version 4.4, Syngene). Two normalizations were performed: ferroportin expression was first normalized with cotransfected HLA(A); then, wild-type ferroportin

expression was set at 100% and the expression of ferroportin variants was normalized to the expression of wild-type ferroportin.

55-FE RELEASE MEASUREMENTS

⁵⁵Fe loading of human apotransferrin was performed as previously described ¹⁸. For iron release experiments, a modification of the protocol described by Schimanski *et al.* ¹⁹ was used. Briefly, HEK293T cells were seeded at 1×10^5 cells per well in 12-well plates, grown for 8h in supplemented DMEM, and preloaded with 20 μ g/ml ⁵⁵Fe-transferrin for 24h before transfection with wild-type or mutated FPN1-V5 plasmid constructs for 15h. Cells were washed once with PBS and cultured in Pro293a-CDM serum-free medium (BioWhittaker) for up to 36h. ⁵⁵Fe exported into the supernatant was collected at various time points, mixed with liquid scintillation fluid (Ultima Gold MV, Packard Bioscience) and counted for 10min in a TRI-CARB 1600 CA scintillation counter (Packard). Percentage ⁵⁵Fe export was calculated using the following formula: (⁵⁵Fe in the supernatant at each time point, divided by cellular ⁵⁵Fe at time zero) x 100.

Supplementary Figure 1.

